Compare Acadia Healthcare Company Inc (ACHC) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Acadia Healthcare Company Inc vs BIO-TECHNE Corp — how do they compare? Acadia Healthcare Company Inc trades at $30.84 (market cap $2.94B), while BIO-TECHNE Corp trades at $70.56 (market cap $11.00B). The key difference: BIO-TECHNE Corp is far larger — about 3.7× Acadia Healthcare Company Inc's market cap, and BIO-TECHNE Corp pays a 0.45% dividend while Acadia Healthcare Company Inc pays none. Which is the better fit depends on your goals.
| ACHC | TECH | |
|---|---|---|
Market Cap | $2.94B | $11.00B |
Sector | Health | Health |
52-Week High | $31.92 | $71.38 |
52-Week Low | $11.68 | $43.31 |
Enterprise Value | $5.45B | $11.08B |
Dividend Yield | — | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACHC trades at $31.09, down 2.57% today but maintains a bullish technical outlook with strong moving average support. The company shows operational strength with three consecutive earnings beats, though profitability remains challenged with a -32.84% net margin. Analyst consensus is strongly bullish with 68% buy ratings, while recent news highlights the company's strategic shift toward profitability and rising behavioral health demand.
The stock presents a mixed opportunity with strong technical momentum and analyst support offset by persistent profitability challenges. Key catalysts include continued earnings outperformance and successful execution of the turnaround strategy, while risks center on margin pressures and high short interest that could limit upside potential.
Bio-Techne (TECH) trades at $70.61, down 0.3% on the day, near its $73.00 takeover offer from Merck KGaA announced June 25, 2026. The stock shows bullish technical signals with strong moving averages, though RSI levels indicate overbought conditions. Fundamentals reveal a high P/E of 101.29 and declining net margins, but revenue remains stable near $1.22 billion. Cash flow improved in 2025 with $10.40M net inflow, and the balance sheet holds $152.86M cash against $319M long-term debt.
Outlook is dominated by the pending acquisition, offering a clear exit at $73.00, a 3.4% premium to current price. Risks include shareholder litigation questioning deal fairness and margin pressures. Analysts are unanimously positive with no sell ratings, seeing limited downside given the buyout bid. The stock presents a low-risk opportunity if the deal closes, but investors face uncertainty from legal challenges and earnings volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Acadia Healthcare Company Inc
Acadia Healthcare is a leading provider of behavioral healthcare services across the US and Puerto Rico. It operates a network of psychiatric hospitals, residential treatment centers, and clinics for mental health and addiction recovery.
Read more on ACHC →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
